Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus
Basic Information
- Device Name
- Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus
- Trade Name
- LIAISON XL MUREX HCV Ab; LIAISON XL MUREX Control HCV Ab
- PMA Number
- P190011
- Device Class
- FDA Class 2
- Product Code
- MZO
- Generic Name
- Assay, enzyme linked immunosorbent, hepatitis c virus
- Medical Specialty
- Unknown
- Advisory Committee
- Microbiology
- Decision
- Approved (Reclassification)
- Decision Code
- APRL
- Decision Date
- October 18, 2019
- Date Received
- April 22, 2019
- Expedited Review
- N
Advisory Committee Statement
Approval for the LIAISON XL MUREX HCV Ab. The LIAISON XL MUREX HCV Ab is an in vitro chemiluminescent immunoassay for the qualitative determination of specific antibodies to hepatitis C virus (anti-HCV) in human adult and pediatric serum and plasma (lithium and sodium heparin, sodium citrate and potassium EDTA) samples including separator tubes, on the LIAISON XL Analyzer. It is intended to be used as an aid in the diagnosis of HCV infection. The assay may also be used as an aid in the diagnosis of HCV infection in pediatric subjects and in pregnant women. The test does not determine the state of infection or associated disease. The assay is not intended for use in screening blood, plasma, or tissue donors.The LIAISON XL MUREX Control HCV Ab (negative and positive) is intended for use as assayed quality control samples to monitor the performance of the LIAISON XL Murex HCV AB assay. The performance characteristics of LIAISON Controls have not been established for any other assays or instrument platforms different from LIAISON XL.
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| MZO | Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus | FDA class 2 | Unknown |